Adimmune Corporation (4142.TW)
TWD 18.85
(-3.83%)
TWD 18.85
(-3.83%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -639.89 Million TWD | -626.6% |
| 2022 | 146.21 Million TWD | 415.24% |
| 2021 | 28.37 Million TWD | -97.71% |
| 2020 | 1.24 Billion TWD | 485.8% |
| 2019 | -321.73 Million TWD | 47.18% |
| 2018 | -609.11 Million TWD | 19.87% |
| 2017 | -760.17 Million TWD | -27.69% |
| 2016 | -595.35 Million TWD | 21.78% |
| 2015 | -761.08 Million TWD | -23.87% |
| 2014 | -614.42 Million TWD | -2.33% |
| 2013 | -600.45 Million TWD | 0.53% |
| 2012 | -603.68 Million TWD | -28.08% |
| 2011 | -471.31 Million TWD | -392.19% |
| 2010 | 161.3 Million TWD | -72.61% |
| 2009 | 588.88 Million TWD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -183.97 Million TWD | 60.13% |
| 2024 Q2 | -273.78 Million TWD | -48.82% |
| 2023 Q4 | -461.36 Million TWD | -274.95% |
| 2023 FY | -769.97 Million TWD | -626.6% |
| 2023 Q3 | 263.7 Million TWD | 209.55% |
| 2023 Q1 | -249.01 Million TWD | -509.79% |
| 2023 Q2 | -240.7 Million TWD | 3.33% |
| 2022 FY | 146.21 Million TWD | 415.24% |
| 2022 Q1 | -249.55 Million TWD | -184.63% |
| 2022 Q2 | -26.18 Million TWD | 89.51% |
| 2022 Q4 | 60.76 Million TWD | -85.52% |
| 2022 Q3 | 419.51 Million TWD | 1702.25% |
| 2021 FY | 28.37 Million TWD | -97.71% |
| 2021 Q4 | 294.86 Million TWD | 83.17% |
| 2021 Q1 | -249.79 Million TWD | -120.14% |
| 2021 Q2 | -162.97 Million TWD | 34.76% |
| 2021 Q3 | 160.97 Million TWD | 198.77% |
| 2020 Q3 | 160.33 Million TWD | 212.36% |
| 2020 Q2 | -142.7 Million TWD | -746.85% |
| 2020 Q1 | -16.85 Million TWD | 23.18% |
| 2020 Q4 | 1.24 Billion TWD | 673.66% |
| 2020 FY | 1.24 Billion TWD | 485.8% |
| 2019 Q3 | 110.54 Million TWD | 164.16% |
| 2019 FY | -321.73 Million TWD | 47.18% |
| 2019 Q1 | -196.98 Million TWD | 43.47% |
| 2019 Q2 | -172.29 Million TWD | 12.53% |
| 2019 Q4 | -21.93 Million TWD | -119.84% |
| 2018 Q3 | -6.02 Million TWD | 92.18% |
| 2018 FY | -609.11 Million TWD | 19.87% |
| 2018 Q4 | -348.48 Million TWD | -5686.85% |
| 2018 Q2 | -77 Million TWD | 56.65% |
| 2018 Q1 | -177.6 Million TWD | 41.46% |
| 2017 Q2 | -148.92 Million TWD | 23.97% |
| 2017 FY | -760.17 Million TWD | -27.69% |
| 2017 Q3 | -111.98 Million TWD | 24.8% |
| 2017 Q1 | -195.86 Million TWD | 8.09% |
| 2017 Q4 | -303.39 Million TWD | -170.91% |
| 2016 Q3 | -128.95 Million TWD | -22.65% |
| 2016 FY | -595.35 Million TWD | 21.78% |
| 2016 Q1 | -148.15 Million TWD | 55.72% |
| 2016 Q2 | -105.14 Million TWD | 29.04% |
| 2016 Q4 | -213.09 Million TWD | -65.25% |
| 2015 Q4 | -334.61 Million TWD | -74.82% |
| 2015 FY | -761.08 Million TWD | -23.87% |
| 2015 Q3 | -191.4 Million TWD | -106.86% |
| 2015 Q1 | -142.54 Million TWD | 37.71% |
| 2015 Q2 | -92.52 Million TWD | 35.09% |
| 2014 Q3 | -250.45 Million TWD | -1590.96% |
| 2014 Q4 | -228.84 Million TWD | 8.63% |
| 2014 Q1 | -151.92 Million TWD | 16.94% |
| 2014 FY | -614.42 Million TWD | -2.33% |
| 2014 Q2 | 16.79 Million TWD | 111.06% |
| 2013 Q3 | -108.28 Million TWD | 23.29% |
| 2013 Q1 | -168.09 Million TWD | 6.49% |
| 2013 FY | -600.45 Million TWD | 0.53% |
| 2013 Q4 | -182.92 Million TWD | -68.93% |
| 2013 Q2 | -141.15 Million TWD | 16.03% |
| 2012 Q2 | -150.88 Million TWD | -12.61% |
| 2012 Q4 | -179.75 Million TWD | -27.91% |
| 2012 Q3 | -140.53 Million TWD | 6.86% |
| 2012 Q1 | -133.98 Million TWD | 22.07% |
| 2012 FY | -603.68 Million TWD | -28.08% |
| 2011 Q3 | -101.88 Million TWD | 19.08% |
| 2011 FY | -471.31 Million TWD | -392.19% |
| 2011 Q4 | -171.93 Million TWD | -68.74% |
| 2011 Q2 | -125.91 Million TWD | -75.9% |
| 2011 Q1 | -71.58 Million TWD | 20.44% |
| 2010 Q3 | -70.96 Million TWD | 0.0% |
| 2010 FY | 161.3 Million TWD | -72.61% |
| 2010 Q4 | -89.97 Million TWD | -26.78% |
| 2009 FY | 588.88 Million TWD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Apex Biotechnology Corp. | 115.78 Million TWD | 652.664% |
| Sinphar Pharmaceutical Co.,Ltd. | 375.17 Million TWD | 270.56% |
| Panion & Bf Biotech Inc. | 77.21 Million TWD | 928.67% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 264.9 Million TWD | 341.551% |
| GenMont Biotech Incorporation | 32.99 Million TWD | 2039.593% |
| Abnova (Taiwan) Corporation | 43.67 Million TWD | 1565.019% |
| Tanvex BioPharma, Inc. | -2.13 Billion TWD | 70.058% |
| Polaris Group | -1.57 Billion TWD | 59.416% |
| Energenesis Biomedical CO.,LTD. | -260.38 Million TWD | -145.751% |
| UnicoCell Biomed Co., Ltd. | -84.1 Million TWD | -660.797% |
| PELL Bio-Med Technology Co. Ltd. | -398.75 Million TWD | -60.472% |